HRP20160127T1 - Biomarkeri raka pluä†a i njihove uporabe - Google Patents
Biomarkeri raka pluä†a i njihove uporabe Download PDFInfo
- Publication number
- HRP20160127T1 HRP20160127T1 HRP20160127TT HRP20160127T HRP20160127T1 HR P20160127 T1 HRP20160127 T1 HR P20160127T1 HR P20160127T T HRP20160127T T HR P20160127TT HR P20160127 T HRP20160127 T HR P20160127T HR P20160127 T1 HRP20160127 T1 HR P20160127T1
- Authority
- HR
- Croatia
- Prior art keywords
- individual
- biomarker
- biomarkers
- biological sample
- lung cancer
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title 1
- 201000005202 lung cancer Diseases 0.000 title 1
- 208000020816 lung neoplasm Diseases 0.000 title 1
- 239000000107 tumor biomarker Substances 0.000 title 1
- 239000000090 biomarker Substances 0.000 claims 25
- 238000000034 method Methods 0.000 claims 23
- 239000012472 biological sample Substances 0.000 claims 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 238000004590 computer program Methods 0.000 claims 5
- 210000004072 lung Anatomy 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 230000000391 smoking effect Effects 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000002380 cytological effect Effects 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 1
- 101710141454 Nucleoprotein Proteins 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
- G06F17/10—Complex mathematical operations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Mathematical Physics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Theoretical Computer Science (AREA)
- Pure & Applied Mathematics (AREA)
- Mathematical Optimization (AREA)
- Algebra (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Databases & Information Systems (AREA)
- Computational Mathematics (AREA)
- Software Systems (AREA)
- Mathematical Analysis (AREA)
Claims (22)
1. Postupak in vitro za dijagnosticiranje raka ne-malih stanica pluća za pojedinca koji ima povijest pušača, naznačen time, da postupak obuhvaća sljedeće:pripremanje popisa izabranih biomarkera koji sadrže N između biomarkerskih proteina u Tablici 1,otkrivanje biomarkerskih proteina, u biološkom uzorku od pojedinca, za dobivanje vrijednosti biomarkera od kojih svaka odgovara jednom od navedenih N biomarkerskih proteina u popisu, pri čemu se vjerojatnost da pojedinac ima rak ne-malih stanica pluća, određuje na temelju navedenih vrijednosti biomarkera, a pritom N = 3 – 61, dok je biološki uzorak odabran iz skupine koju čine puna krv, plazma, serum i plućno tkivo.
2. Postupak prema zahtjevu 1, naznačen time, da u popisu izabranih biomarkera vrijednost senzitivnosti plus vrijednost specifičnosti iznosi 1,65 ili više, pri čemu N = 4 – 61.
3. Postupak prema zahtjevu 1, naznačen time, da u popisu izabranih biomarkera vrijednost senzitivnosti plus vrijednost specifičnosti iznosi 1,70 ili više, pri čemu N = 6 – 61.
4. Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da otkrivanje vrijednosti biomarkera, obuhvaća izvođenje testiranja in vitro.
5. Postupak prema zahtjevu 4, naznačen time, da navedeno testiranje in vitro sadrži najmanje jedan sakupljački reagens koji odgovara svakom od navedenih biomarkera, te nadalje obuhvaća odabir navedenog barem jednog sakupljačkog reagensa iz skupine koju čine aptameri i protutijela.
6. Postupak prema zahtjevu 4, naznačen time, da je navedeno testiranje in vitro odabrano iz skupine koju čine imunološko testiranje, testiranje na bazi aptamera i histološko ili citološko testiranje.
7. Postupak prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se svaka vrijednost biomarkera ocjenjuje na temelju predodređene vrijednosti ili predodređenog raspona vrijednosti.
8. Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time, da je biološki uzorak plućno tkivo i pritom se vrijednosti biomarkera izvode iz histoloških i citoloških analiza navedenog plućnog tkiva.
9. Postupak s primjenjenim računalnim sustavom za prikazivanje stanja gdje pojedinac s povijesti pušača, ima ili nema rak ne-malih stanica pluća,naznačen time, da postupak obuhvaća sljedeće:pripremanje popisa izabranih biomarkera koji sadrže N od biomarkerskih proteina u Tablici 1,prijenos podataka u računalo koji sadrže biomarkerske informacije otkrivene u biološkom uzorku od pojedinca, gdje biomarkerske informacije sadrže vrijednosti biomarkera, od kojih svaka odgovara jednom od navedenih N biomarkerskih proteina u popisu, dok je biološki uzorak odabran iz skupine koju čine puna krv, plazma, serum i plućno tkivo;izvođenje klasifikacije putem računalnog sustava za svaku od vrijednosti biomarkera; i nagovještavanje vjerojatnosti da navedeni pojedinac ima rak ne-malih stanica pluća, koja se temelji na velikom broju klasifikacija, te je pritom N = 3 – 61.
10. Postupak prema zahtjevu 9, naznačen time, da nagovještavanje vjerojatnosti prema kojoj navedeni pojedinac ima rak ne-malih stanica pluća, obuhvaća prikazivanje takve vjerojatnosti na ekranu računala.
11. Postupak prema bilo kojem od zahtjeva 1, 2 ili 4 do 10, naznačen time, da N = 4 – 61 ili N = 5 – 61.
12. Postupak prema bilo kojem od zahtjeva 1, 2 ili 4 do 10, naznačen time, da N = 5 – 15.
13. Postupak prema bilo kojem od zahtjeva 1, 2 ili 4 do 10, naznačen time, da N = 5 – 10.
14. Postupak prema bilo kojem od zahtjeva 1 do 13, naznačen time, da pojedinac je čovjek.
15. Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time, da pojedinac je pušač.
16. Postupak prema zahtjevu 15, naznačen time, da su biomarkeri odabrani između onih koji su označeni s „X“ u Tablici 1, stupac br. 6.
17. Postupak prema bilo kojem od zahtjeva 1 do 16, naznačen time, da pojedinac ima plućnu kvržicu.
18. Postupak prema zahtjevu 17, naznačen time, da su biomarkeri odabrani između onih koji su označeni s „X“ u Tablici 1, stupac br. 5.
19. Proizvod računalnog programa za nagovještavanje vjerojatnosti da pojedinac s povijesti pušača, ima ili nema rak ne-malih stanica pluća, naznačen time, da proizvod računalnog programa obuhvaća sljedeće:računalni medij s mogućnošću očitavanja, koji obuhvaća programski kôd za izvršavanje programa putem procesora računalnog uređaja ili računalnog sustava, pri čemu programski kôd obuhvaća sljedeće:kôd koji dohvaća podatke pripisane na biološkom uzorku od pojedinca, dok ti podaci obuhvaćaju vrijednosti biomarkera, od kojih svaka odgovara jednom od najmanje N proteinskih biomarkera odabranih iz Tablice 1, gdje su navedeni proteinski biomarkeri otkriveni u biološkom uzorku, pri čemu je biološki uzorak odabran iz skupine koju čine puna krv, plazma, serum i plućno tkivo; i kôd za izvršavanje postupka klasifikacije koja pokazuje stanje plućne bolesti za pojedinca, kao funkciju navedenih vrijednosti biomarkera; te je pritom N = 3 – 61.
20. Proizvod računalnog programa prema zahtjevu 19, naznačen time, da N = 4 – 61 ili N = 5 – 61.
21. Proizvod računalnog programa prema zahtjevu 19 ili 20, naznačen time, da se spomenuti postupak klasifikacije koristi funkcijom mogućnosti gustoće.
22. Proizvod računalnog programa prema zahtjevu 21, naznačen time, da spomenuti postupak klasifikacije upotrebljava dvije ili više klasa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9559308P | 2008-09-09 | 2008-09-09 | |
| US15283709P | 2009-02-16 | 2009-02-16 | |
| PCT/US2009/056399 WO2010030697A1 (en) | 2008-09-09 | 2009-09-09 | Lung cancer biomarkers and uses thereof |
| EP09813557.7A EP2340506B1 (en) | 2008-09-09 | 2009-09-09 | Lung cancer biomarkers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160127T1 true HRP20160127T1 (hr) | 2016-03-11 |
Family
ID=42005456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160127TT HRP20160127T1 (hr) | 2008-09-09 | 2016-02-04 | Biomarkeri raka pluä†a i njihove uporabe |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2340506B1 (hr) |
| JP (1) | JP5701212B2 (hr) |
| KR (1) | KR101658347B1 (hr) |
| CN (2) | CN104198709A (hr) |
| AU (2) | AU2009291811B2 (hr) |
| CA (3) | CA3011730C (hr) |
| DK (1) | DK2340506T3 (hr) |
| ES (1) | ES2559758T3 (hr) |
| GB (1) | GB2478441B (hr) |
| HK (2) | HK1153834A1 (hr) |
| HR (1) | HRP20160127T1 (hr) |
| MX (1) | MX2011002322A (hr) |
| SI (1) | SI2340506T1 (hr) |
| WO (1) | WO2010030697A1 (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10359425B2 (en) | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| EP3444359A1 (en) | 2009-03-12 | 2019-02-20 | Cancer Prevention And Cure, Ltd. | Methods of identification of non-small cell lung cancer |
| AU2011274422B2 (en) * | 2010-07-09 | 2016-02-11 | Somalogic Operating Co., Inc. | Lung cancer biomarkers and uses thereof |
| WO2012021795A2 (en) | 2010-08-13 | 2012-02-16 | Somalogic, Inc. | Pancreatic cancer biomarkers and uses thereof |
| RU2612017C2 (ru) * | 2011-04-07 | 2017-03-01 | Де Скриппс Рисерч Инститьют | Высокопроизводительный скрининг соединений, модулирующих экспрессию клеточных макромолекул |
| EP2702411A4 (en) | 2011-04-29 | 2015-07-22 | Cancer Prevention & Cure Ltd | METHODS OF IDENTIFYING AND DIAGNOSING PULMONARY DISEASES USING CLASSIFICATION SYSTEMS AND THEIR KITS |
| KR101921945B1 (ko) * | 2011-10-24 | 2018-11-26 | 소마로직, 인크. | 폐암 바이오마커 및 그것의 용도 |
| US11913957B2 (en) | 2011-12-21 | 2024-02-27 | Biodesix, Inc. | Compositions, methods and kits for diagnosis of lung cancer |
| US9201044B2 (en) | 2011-12-21 | 2015-12-01 | Integrated Diagnostics, Inc. | Compositions, methods and kits for diagnosis of lung cancer |
| US9304137B2 (en) | 2011-12-21 | 2016-04-05 | Integrated Diagnostics, Inc. | Compositions, methods and kits for diagnosis of lung cancer |
| BR112014020040A8 (pt) * | 2012-02-17 | 2017-07-11 | Koninklijke Philips Nv | Meio de armazenamento não transitório que armazena as instruções executáveis por um dispositivo de processamento eletrônico de dados que inclui um visor para o monitoramento de um paciente com lesão pulmonar aguda, aparelho, e, método |
| CN104812913B (zh) | 2012-11-07 | 2019-03-15 | 私募蛋白质体公司 | 慢性阻塞性肺疾病(copd)生物标记及其用途 |
| CA2928271C (en) * | 2013-11-07 | 2022-05-31 | Medial Research Ltd. | Methods and systems of evaluating a risk of lung cancer |
| KR102078310B1 (ko) * | 2015-09-11 | 2020-02-19 | 주식회사 압타머사이언스 | 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법 |
| FR3050269B1 (fr) | 2016-04-15 | 2018-05-11 | Ecole Superieure De Physique Et De Chimie Industrielles De La Ville De Paris (Espci) | Procede de selection et de recuperation de produits et systeme associe |
| CN105823665A (zh) * | 2016-05-13 | 2016-08-03 | 北京九州柏林生物科技有限公司 | 生物组织样本制备套液 |
| CN109715830A (zh) | 2016-06-21 | 2019-05-03 | 威斯塔解剖学和生物学研究所 | 用于使用基因表达谱诊断肺癌的组合物和方法 |
| JP6280997B1 (ja) * | 2016-10-31 | 2018-02-14 | 株式会社Ｐｒｅｆｅｒｒｅｄ Ｎｅｔｗｏｒｋｓ | 疾患の罹患判定装置、疾患の罹患判定方法、疾患の特徴抽出装置及び疾患の特徴抽出方法 |
| CA3058481A1 (en) | 2017-04-04 | 2018-10-11 | Lung Cancer Proteomics, Llc | Plasma based protein profiling for early stage lung cancer prognosis |
| CN111148844A (zh) | 2017-09-01 | 2020-05-12 | 韦恩生物科技股份公司 | 鉴定和使用糖肽作为诊断和治疗监测的生物标记物 |
| EP3714275A4 (en) * | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| US20210247387A1 (en) * | 2018-06-22 | 2021-08-12 | Somalogic, Inc. | Improved proteomic multiplex assays |
| CN114026424A (zh) * | 2019-06-21 | 2022-02-08 | 新加坡国立大学 | 用于确定肺癌的可能性的方法 |
| CN110579611B (zh) * | 2019-09-18 | 2023-01-31 | 郑州大学 | 一种用于肺癌早期筛查和诊断的联合检测血清标志物、试剂盒及检测方法 |
| CN111047609B (zh) * | 2020-03-13 | 2020-07-24 | 北京深睿博联科技有限责任公司 | 肺炎病灶分割方法和装置 |
| CN116381073A (zh) * | 2020-10-10 | 2023-07-04 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 生物标志物在制备肺癌检测试剂中的用途和方法 |
| CN112557514B (zh) * | 2020-12-22 | 2021-09-21 | 中国海洋大学 | 手持式海底沉积物样品剖面声学全自动测量装置 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596503B1 (en) * | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
| CN1554025A (zh) * | 2001-03-12 | 2004-12-08 | Īŵ���ɷ�����˾ | 患病状态的细胞为基础的检测和鉴别 |
| US20030190602A1 (en) * | 2001-03-12 | 2003-10-09 | Monogen, Inc. | Cell-based detection and differentiation of disease states |
| AU2002309583A1 (en) * | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| US8014952B2 (en) * | 2002-12-18 | 2011-09-06 | Queen Elizabeth Hospital | Serum biomarkers in lung cancer |
| CN1225477C (zh) * | 2003-03-28 | 2005-11-02 | 上海市疾病预防控制中心 | 肺癌早期血清特异蛋白及其应用 |
| CN1455257A (zh) * | 2003-05-23 | 2003-11-12 | 北京师范大学 | 一种利用表面修饰蛋白芯片进行肺癌诊断方法 |
| TW200600785A (en) * | 2004-03-23 | 2006-01-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancer |
| JP2005304497A (ja) * | 2004-03-25 | 2005-11-04 | Joji Inasawa | 特定の癌関連遺伝子を用いる癌の検出方法及び癌の抑制方法 |
| ES2367311T3 (es) * | 2004-04-15 | 2011-11-02 | University Of Florida Research Foundation, Inc. | Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales. |
| EP1743031A4 (en) * | 2004-04-26 | 2008-05-28 | Childrens Medical Center | BLOOD PLATE BIOMARKERS FOR THE DETECTION OF ILLNESSES |
| US8173433B2 (en) * | 2004-08-02 | 2012-05-08 | Vermillion, Inc. | Platelet biomarkers for cancer |
| CN1873417A (zh) * | 2005-06-02 | 2006-12-06 | 中国医学科学院肿瘤医院肿瘤研究所 | 一种用于诊断肺癌的蛋白质芯片 |
| US20070178504A1 (en) * | 2005-12-22 | 2007-08-02 | Tracey Colpitts | Methods and marker combinations for screening for predisposition to lung cancer |
| US7908091B2 (en) * | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| AU2007313551A1 (en) * | 2006-10-17 | 2008-04-24 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
| WO2008097908A2 (en) * | 2007-02-05 | 2008-08-14 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and prognosing lung cancer |
| KR100846354B1 (ko) * | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
| WO2008144512A1 (en) * | 2007-05-18 | 2008-11-27 | University Of Southern California | Germline polymorphisms in the angiogenic pathway predict tumor recurrence in cancer therapy |
| US7888051B2 (en) * | 2007-09-11 | 2011-02-15 | Cancer Prevention And Cure, Ltd. | Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues |
| WO2010003772A1 (en) * | 2008-06-16 | 2010-01-14 | Siemens Medical Solutions Diagnostics Gmbh | Method for predicting adverse response to erythropoietin in breast cancer treatment |
| US10359425B2 (en) * | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| KR101824746B1 (ko) * | 2010-02-10 | 2018-02-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 폐암 검출용 타액 바이오마커 |
-
2009
- 2009-09-09 ES ES09813557.7T patent/ES2559758T3/es active Active
- 2009-09-09 JP JP2011526308A patent/JP5701212B2/ja active Active
- 2009-09-09 KR KR1020117005305A patent/KR101658347B1/ko active IP Right Grant
- 2009-09-09 CA CA3011730A patent/CA3011730C/en active Active
- 2009-09-09 WO PCT/US2009/056399 patent/WO2010030697A1/en active Application Filing
- 2009-09-09 CN CN201410477840.7A patent/CN104198709A/zh active Pending
- 2009-09-09 CA CA2734535A patent/CA2734535C/en active Active
- 2009-09-09 SI SI200931363T patent/SI2340506T1/sl unknown
- 2009-09-09 DK DK09813557.7T patent/DK2340506T3/en active
- 2009-09-09 EP EP09813557.7A patent/EP2340506B1/en active Active
- 2009-09-09 MX MX2011002322A patent/MX2011002322A/es active IP Right Grant
- 2009-09-09 GB GB1106053.0A patent/GB2478441B/en active Active
- 2009-09-09 CN CN200980144620.XA patent/CN102209968B/zh active Active
- 2009-09-09 AU AU2009291811A patent/AU2009291811B2/en active Active
- 2009-09-09 CA CA3152591A patent/CA3152591C/en active Active
-
2011
- 2011-07-29 HK HK11107896.7A patent/HK1153834A1/xx unknown
-
2015
- 2015-05-18 HK HK15104677.5A patent/HK1204062A1/xx unknown
- 2015-10-29 AU AU2015249113A patent/AU2015249113B2/en active Active
-
2016
- 2016-02-04 HR HRP20160127TT patent/HRP20160127T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2559758T3 (es) | 2016-02-15 |
| AU2015249113B2 (en) | 2017-09-07 |
| EP2340506A1 (en) | 2011-07-06 |
| GB2478441B (en) | 2013-03-27 |
| KR101658347B1 (ko) | 2016-09-21 |
| KR20110063753A (ko) | 2011-06-14 |
| MX2011002322A (es) | 2011-05-10 |
| CA3011730A1 (en) | 2010-03-18 |
| CA2734535C (en) | 2018-08-28 |
| CN102209968A (zh) | 2011-10-05 |
| AU2009291811B2 (en) | 2015-10-29 |
| EP2340506A4 (en) | 2012-02-15 |
| EP2340506B1 (en) | 2015-11-11 |
| CA3152591A1 (en) | 2010-03-18 |
| SI2340506T1 (sl) | 2016-02-29 |
| DK2340506T3 (en) | 2016-02-08 |
| CA3152591C (en) | 2023-08-29 |
| GB2478441A (en) | 2011-09-07 |
| JP5701212B2 (ja) | 2015-04-15 |
| HK1153834A1 (en) | 2012-04-05 |
| CN104198709A (zh) | 2014-12-10 |
| GB201106053D0 (en) | 2011-05-25 |
| CN102209968B (zh) | 2016-05-04 |
| CA2734535A1 (en) | 2010-03-18 |
| HK1204062A1 (en) | 2015-11-06 |
| JP2012502281A (ja) | 2012-01-26 |
| CA3011730C (en) | 2022-05-17 |
| AU2009291811A1 (en) | 2010-03-18 |
| AU2015249113A1 (en) | 2015-11-12 |
| WO2010030697A1 (en) | 2010-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160127T1 (hr) | Biomarkeri raka pluä†a i njihove uporabe | |
| Wolock et al. | Scrublet: computational identification of cell doublets in single-cell transcriptomic data | |
| Stadler et al. | Immunofluorescence and fluorescent-protein tagging show high correlation for protein localization in mammalian cells | |
| Illingworth et al. | ICCS/ESCCA consensus guidelines to detect GPI‐deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 3–data analysis, reporting and case studies | |
| Frantzi et al. | Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development | |
| CN106198980B (zh) | 胰腺癌生物标记及其用途 | |
| JP2012502281A5 (hr) | ||
| Taefi et al. | Red cell distribution width to platelet ratio, a useful indicator of liver fibrosis in chronic hepatitis patients | |
| CN104777313B (zh) | 肺癌生物标记及其用途 | |
| CN105209909B (zh) | 与肾功能相关的生物标记及其使用方法 | |
| JP2013532295A5 (hr) | ||
| CN103890586A (zh) | 肺癌生物标记及其用途 | |
| CN103958662A (zh) | 用于疾病生物标记鉴定和样品质量评价的优选样品处理和加工方案的选择 | |
| CN105588944B (zh) | 检测agp1、serpina3和cdh1含量的系统在筛查活动性结核病患者中的应用 | |
| Ioannidis | A roadmap for successful applications of clinical proteomics | |
| US20200188907A1 (en) | Marker analysis for quality control and disease detection | |
| Savage | Proteomics: High-protein research | |
| Cappellini et al. | Heart-type fatty acid-binding protein may exclude acute myocardial infarction on admission to emergency department for chest pain | |
| Haselbeck et al. | Serology as a tool to assess infectious disease landscapes and guide public health policy | |
| CN108474798A (zh) | 表征细胞特异性微囊泡的方法 | |
| CN107169264B (zh) | 一种复杂疾病诊断系统 | |
| Schneider et al. | The utility of differential scanning calorimetry curves of blood plasma for diagnosis, subtype differentiation and predicted survival in lung cancer | |
| Huang | Altitudinal patterns of Stereocaulon (lichenized Ascomycota) in China | |
| Chao et al. | Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery | |
| Haab | Antibody–lectin sandwich arrays for biomarker and glycobiology studies |